Amespro Fluorinated-Nicotinamide (18F)
Image for illustration purposes only.
Used for the diagnosis and staging of prostate cancer.
Manufactured and distributed by:
São José do Rio Preto/SP location (Official Letter No 4754588227)
- Presentation: shielded packaging containing 1 multidose vial.
- Pharmaceutical form: Sterile solution.
- Route of administration: Intravenous.
- Ingredients: Each mL of solution contains 555-5550 MBq of Amespro Fluorinated-Nicotinamide (18F) at the reference time, with a maximum of 10 ml per vial.
- Excipients: Each mL of solution contains up to 80 mg of ethanol, 6 mg of sodium, 0.1 mg of potassium.
- Physical half-life: 110 minutes.
- Indication: Amespro Fluorinated-Nicotinamide (18F) is indicated for imaging using Positron Emission Tomography (PET) in order to locate recurrent prostate cancer in adult men with suspicion of elevation of serum levels of prostate-specific antigen (PSA).
Duque de Caxias/RJ location (Official Letter No 0972796215)
- Presentation: shielded packaging containing 1 multidose vial.
- Pharmaceutical form: Sterile solution.
- Route of administration: Intravenous.
- Ingredients: Each mL of solution contains: up to 10 mL.
- Excipients: 0.9% Sodium Chloride and water for injection.
- Physical half-life: 109.7 minutes.
- Indication: Amespro Fluorinated-Nicotinamide (18F) is indicated for imaging using Positron Emission Tomography (PET) in order to locate recurrent prostate cancer in adult men with suspicion of elevation of serum levels of prostate-specific antigen (PSA).
Porto Alegre/RS in partnership with InsCer – PUCRS (Official letter No. 0023362235)
- Presentation: shielded packaging containing 1 multidose vial.
- Pharmaceutical form: Sterile solution.
- Route of administration: Intravenous.
-
Ingredients: Each vial may contain up to 14 mL of:
Amespro Fluorinated-Nicotinamide (18F) 296 MBq (8 mCi) at the date and time of calibration;
Amespro Fluorinated-Nicotinamide (18F) 592 MBq (16 mCi) at the date and time of calibration;
Amespro Fluorinated-Nicotinamide (18F) 888 MBq (24 mCi) at the date and time of calibration;
Amespro Fluorinated-Nicotinamide (18F) 1184 MBq (32 mCi) at the date and time of calibration
Amespro Fluorinated-Nicotinamide (18F) 1480 MBq (40 mCi) at the date and time of calibration
Amespro Fluorinated-Nicotinamide (18F) 1776 MBq (48 mCi) at the date and time of calibration
Amespro Fluorinated-Nicotinamide (18F) 2072 MBq (56 mCi) at the date and time of calibration
Amespro Fluorinated-Nicotinamide (18F) 2368 MBq (64 mCi) at the date and time of calibration
Amespro Fluorinated-Nicotinamide (18F) 2664 MBq (72 mCi) at the date and time of calibration
Amespro Fluorinated-Nicotinamide (18F) 2960 MBq (80 mCi) at the date and time of calibration
Amespro Fluorinated-Nicotinamide (18F) 3256 MBq (88 mCi) at the date and time of calibration - Excipients: Disodium hydrogen phosphate, potassium dihydrogen phosphate, sodium chloride, potassium chloride, ethanol, water for injection, and sodium ascorbate.
- Physical half-life: 110 minutes.
- Indication: Amespro Fluorinated-Nicotinamide (18F) is indicated for imaging using Positron Emission Tomography (PET) in order to locate recurrent prostate cancer in adult men with suspicion of elevation of serum levels of prostate-specific antigen (PSA).
R2Pharma products are available only by means of medical prescription from a licensed physician.
IF SYMPTOMS PERSIST, A DOCTOR SHOULD BE CONSULTED.
Contraindications, warnings, adverse reactions, drug interactions, precautions and posology: refer to package leaflet.
The content of this page is destined to health professionals.